Drug Profile
BAX 555
Alternative Names: 5-HMF - AesRx; 5-hydroxymethyl furfural; Aes-103Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Virginia Commonwealth University
- Developer AesRx; National Institutes of Health (USA); Takeda
- Class Antianaemics; Small molecules
- Mechanism of Action Haemoglobin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sickle cell anaemia
Most Recent Events
- 19 Dec 2019 No development reported - Phase-II for Sickle cell anaemia in United Kingdom (PO)
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 03 Jun 2016 Baxalta has been acquired and merged into Shire